RU2014108478A - Клеточная композиция, фармацевтическая композиция, набор и способ лечения дегенеративного заболевания сетчатки глаза (варианты) - Google Patents
Клеточная композиция, фармацевтическая композиция, набор и способ лечения дегенеративного заболевания сетчатки глаза (варианты) Download PDFInfo
- Publication number
- RU2014108478A RU2014108478A RU2014108478/10A RU2014108478A RU2014108478A RU 2014108478 A RU2014108478 A RU 2014108478A RU 2014108478/10 A RU2014108478/10 A RU 2014108478/10A RU 2014108478 A RU2014108478 A RU 2014108478A RU 2014108478 A RU2014108478 A RU 2014108478A
- Authority
- RU
- Russia
- Prior art keywords
- wnt
- signaling pathway
- stem cell
- catenin signaling
- cell
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 10
- 230000003412 degenerative effect Effects 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 102000013814 Wnt Human genes 0.000 claims abstract 31
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract 31
- 102000015735 Beta-catenin Human genes 0.000 claims abstract 30
- 108060000903 Beta-catenin Proteins 0.000 claims abstract 30
- 230000019491 signal transduction Effects 0.000 claims abstract 28
- 210000004027 cell Anatomy 0.000 claims abstract 25
- -1 indan-5-yloxy Chemical group 0.000 claims abstract 17
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract 16
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims abstract 14
- 239000012190 activator Substances 0.000 claims abstract 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract 12
- 239000003112 inhibitor Substances 0.000 claims abstract 12
- 125000005842 heteroatom Chemical group 0.000 claims abstract 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 11
- 210000001525 retina Anatomy 0.000 claims abstract 11
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 7
- ALJIEVIJBAJISI-NCELDCMTSA-N (2e)-2-[(4-acetylphenyl)hydrazinylidene]-2-(3,3-dimethyl-4h-isoquinolin-1-yl)acetamide Chemical compound C1=CC(C(=O)C)=CC=C1N\N=C(\C(N)=O)C1=NC(C)(C)CC2=CC=CC=C12 ALJIEVIJBAJISI-NCELDCMTSA-N 0.000 claims abstract 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims abstract 6
- 230000004913 activation Effects 0.000 claims abstract 6
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims abstract 6
- 229960003964 deoxycholic acid Drugs 0.000 claims abstract 6
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims abstract 6
- 238000002513 implantation Methods 0.000 claims abstract 4
- 210000000130 stem cell Anatomy 0.000 claims abstract 4
- MDWJZBVEVLTXDE-UHFFFAOYSA-N 2-methyl-1h-indol-5-ol Chemical compound OC1=CC=C2NC(C)=CC2=C1 MDWJZBVEVLTXDE-UHFFFAOYSA-N 0.000 claims abstract 3
- GOVXKUCVZUROAN-UHFFFAOYSA-N 3-ethyl-1h-indole Chemical compound C1=CC=C2C(CC)=CNC2=C1 GOVXKUCVZUROAN-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims abstract 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims abstract 3
- FABQUVYDAXWUQP-UHFFFAOYSA-N N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(C=2N=C(N)N=C(NCC=3C=C4OCOC4=CC=3)C=2)=C1 FABQUVYDAXWUQP-UHFFFAOYSA-N 0.000 claims abstract 3
- 102000001708 Protein Isoforms Human genes 0.000 claims abstract 3
- 108010029485 Protein Isoforms Proteins 0.000 claims abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 3
- 230000007850 degeneration Effects 0.000 claims 9
- 208000002780 macular degeneration Diseases 0.000 claims 9
- 206010010356 Congenital anomaly Diseases 0.000 claims 8
- 206010064930 age-related macular degeneration Diseases 0.000 claims 6
- 239000002243 precursor Substances 0.000 claims 4
- 208000002177 Cataract Diseases 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 3
- 208000001140 Night Blindness Diseases 0.000 claims 3
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 208000027073 Stargardt disease Diseases 0.000 claims 3
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 230000007170 pathology Effects 0.000 claims 3
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 claims 2
- BHFFSIFXFHJJNJ-UHFFFAOYSA-N 5-(benzenesulfonyl)-n-[3-(dimethylamino)propyl]-2-ethylbenzenesulfonamide Chemical compound C1=C(S(=O)(=O)NCCCN(C)C)C(CC)=CC=C1S(=O)(=O)C1=CC=CC=C1 BHFFSIFXFHJJNJ-UHFFFAOYSA-N 0.000 claims 2
- 241000508725 Elymus repens Species 0.000 claims 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- 201000006754 cone-rod dystrophy Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000008672 reprogramming Effects 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims 1
- 208000014769 Usher Syndromes Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000790 retinal pigment Substances 0.000 claims 1
- 210000004127 vitreous body Anatomy 0.000 claims 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 abstract 1
- XTVTWYSUSYRBQW-RGURZIINSA-N OC[C@H](Cc1c[nH]cn1)NC1N=CC=CN1 Chemical compound OC[C@H](Cc1c[nH]cn1)NC1N=CC=CN1 XTVTWYSUSYRBQW-RGURZIINSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11176713.3 | 2011-08-05 | ||
| EP11176713A EP2554662A1 (en) | 2011-08-05 | 2011-08-05 | Methods of treatment of retinal degeneration diseases |
| PCT/EP2012/065327 WO2013020945A1 (en) | 2011-08-05 | 2012-08-06 | Methods of treatment of retinal degeneration diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014108478A true RU2014108478A (ru) | 2015-09-10 |
Family
ID=46826437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014108478/10A RU2014108478A (ru) | 2011-08-05 | 2012-08-06 | Клеточная композиция, фармацевтическая композиция, набор и способ лечения дегенеративного заболевания сетчатки глаза (варианты) |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20140199277A1 (OSRAM) |
| EP (2) | EP2554662A1 (OSRAM) |
| JP (1) | JP2014527407A (OSRAM) |
| KR (1) | KR20140068936A (OSRAM) |
| CN (1) | CN104011203A (OSRAM) |
| AR (1) | AR087471A1 (OSRAM) |
| AU (1) | AU2012293681A1 (OSRAM) |
| BR (1) | BR112014002718A8 (OSRAM) |
| CA (1) | CA2844106A1 (OSRAM) |
| CO (1) | CO7081142A2 (OSRAM) |
| IL (1) | IL230830A0 (OSRAM) |
| MX (1) | MX2014001475A (OSRAM) |
| RU (1) | RU2014108478A (OSRAM) |
| SG (1) | SG2014008080A (OSRAM) |
| WO (1) | WO2013020945A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013045694A1 (en) * | 2011-09-29 | 2013-04-04 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Compositions and methods for the treatment of degenerative retinal conditions |
| US11724005B2 (en) | 2014-01-17 | 2023-08-15 | Sumitomo Chemical Company, Limited | Method for manufacturing ciliary margin stem cells |
| CA3280614A1 (en) * | 2014-09-16 | 2026-03-02 | Genzyme Corporation | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma |
| RU2569481C1 (ru) * | 2014-12-25 | 2015-11-27 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ получения культуры клеток ретинального пигментного эпителия из глаза взрослого донора-трупа |
| RU2578526C1 (ru) * | 2014-12-25 | 2016-03-27 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ получения органной культуры хороидально-пигментного комплекса из глаза взрослого донора-трупа |
| KR101779932B1 (ko) * | 2015-09-15 | 2017-09-21 | 주식회사 스템랩 | 나노그(Nanog)를 도입한 양수 내 태아 유래 중간엽 줄기세포를 이용한 육모 촉진용 조성물의 제조방법 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| KR101674622B1 (ko) * | 2016-07-07 | 2016-11-09 | 국민대학교산학협력단 | 세스퀴테르펜 유도체의 신규한 용도 |
| US11040019B2 (en) * | 2016-08-19 | 2021-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration |
| CN110267972A (zh) * | 2016-11-06 | 2019-09-20 | 纳秒示波器科技有限公司 | 由多特征视蛋白进行的用于视力恢复的光学调制以及其其他应用 |
| CN111095261A (zh) | 2017-04-27 | 2020-05-01 | 视网膜病答案有限公司 | 眼底图像自动分析系统和方法 |
| MX394108B (es) | 2017-05-18 | 2025-03-21 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos. |
| CN110612296A (zh) | 2017-05-18 | 2019-12-24 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯基衍生物 |
| JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
| TW201900180A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 嘧啶衍生物 |
| AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| EP3638265A4 (en) * | 2017-06-15 | 2021-04-14 | University of North Texas Health Science Center | Reprogramming fibroblasts to retinal cells |
| CN111132664A (zh) * | 2017-08-20 | 2020-05-08 | 加州大学董事会 | 治疗青光眼的Wnt5a的调节 |
| WO2019195717A1 (en) * | 2018-04-06 | 2019-10-10 | Icahn School Of Medicine At Mount Sinai | Compositions and methods of treatment of vision loss through generation of rod photoreceptors from müller glial cells |
| US20230090462A1 (en) * | 2019-03-15 | 2023-03-23 | The Schepens Eye Research Institute, Inc. | Isolation, enrichment and expansion of cone progenitor cells and uses thereof |
| CN110706164A (zh) * | 2019-09-03 | 2020-01-17 | 北京爱博同心医学科技有限公司 | 基于增强现实的管状视野图像变形显示方法及眼镜 |
| WO2021062022A1 (en) * | 2019-09-25 | 2021-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Metabolic rescue of retinal degeneration |
| KR20210119766A (ko) * | 2020-03-25 | 2021-10-06 | 서울대학교병원 | 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물 |
| KR102655748B1 (ko) * | 2023-06-08 | 2024-04-05 | 충북대학교 산학협력단 | 고포도당 조건에서의 중간엽 줄기세포의 생존율을 증가시키는 방법 |
| KR102655735B1 (ko) * | 2023-06-09 | 2024-04-05 | 충북대학교 산학협력단 | 당뇨성 망막병증의 예방 및 치료를 위한 타크로리무스 전처리 줄기세포 |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6128654A (en) | 1997-02-14 | 2000-10-03 | Advanced Micro Devices, Inc. | Method and apparatus for transmitting multiple copies by replicating data identifiers |
| US6417185B1 (en) | 1998-06-19 | 2002-07-09 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| PT1237880E (pt) | 1999-12-17 | 2008-03-05 | Novartis Vaccines & Diagnostic | Inibidores baseados em pirazina da cinase 3 da glicogénio sintase |
| CN100335479C (zh) | 1999-12-17 | 2007-09-05 | 希龙公司 | 糖元合成酶激酶3的双环抑制剂 |
| JP2004514656A (ja) | 2000-09-06 | 2004-05-20 | カイロン コーポレイション | グリコゲンシンターゼキナーゼ３のインヒビター |
| JP4361727B2 (ja) | 2000-09-11 | 2009-11-11 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | チロシンキナーゼインヒビターとしてのキノリノン誘導体 |
| CA2446756C (en) | 2001-06-01 | 2011-03-08 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
| RU2004126671A (ru) | 2002-02-06 | 2005-04-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероарилсоединения, полезные в качестве ингибиторов gsk-3 |
| AU2003220026A1 (en) | 2002-03-01 | 2003-09-16 | Chiron Corporation | Methods and compositions for the treatment of ischemia |
| US7838290B2 (en) * | 2002-07-25 | 2010-11-23 | The Scripps Research Institute | Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith |
| US20050129665A1 (en) * | 2002-07-25 | 2005-06-16 | Martin Friedlander | Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
| JP2006501243A (ja) | 2002-08-23 | 2006-01-12 | カイロン コーポレイション | グリコーゲンシンターゼキナーゼ３のピロールベースのインヒビター |
| EP1556355A1 (en) | 2002-10-21 | 2005-07-27 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| BRPI0409861A (pt) * | 2003-05-02 | 2006-05-16 | Scripps Research Inst | células- tronco hematopoiéticas e sua utilização em métodos de tratamento de doenças oculares neovasculares |
| JP2007502300A (ja) | 2003-08-13 | 2007-02-08 | カイロン コーポレイション | Ｇｓｋ−３インヒビターおよびその使用 |
| AU2005285246B2 (en) * | 2004-09-03 | 2011-07-21 | The Scripps Research Institute | Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
| US7850960B2 (en) * | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
| AU2006216473B2 (en) | 2005-02-24 | 2012-07-26 | The Scripps Research Institute | Method for the treatment of retinopathy of prematurity and related retinopathic diseases |
| US20070231306A1 (en) * | 2005-02-24 | 2007-10-04 | The Scripps Research Institute | Isolated myeloid-like cell populations and methods of treatment therewith |
| EP1888123B1 (en) * | 2005-06-08 | 2013-01-09 | Janssen Biotech, Inc. | A cellular therapy for ocular degeneration |
| US8354370B2 (en) * | 2007-06-15 | 2013-01-15 | Garnet Biotherapeutics, Inc. | Administering a biological composition or compositions isolated from self-renewing colony forming somatic cell growth medium to treat diseases and disorders |
| EP2090649A1 (en) | 2008-02-13 | 2009-08-19 | Fondazione Telethon | Method for reprogramming differentiated cells |
| GB0816577D0 (en) * | 2008-09-11 | 2008-10-15 | Axordia Ltd | Growth factor |
| EP2486126B1 (en) * | 2009-10-06 | 2017-12-06 | SNU R & DB Foundation | Method for differentiation into retinal cells from stem cells |
-
2011
- 2011-08-05 EP EP11176713A patent/EP2554662A1/en not_active Withdrawn
-
2012
- 2012-08-06 AR ARP120102872A patent/AR087471A1/es unknown
- 2012-08-06 US US14/237,297 patent/US20140199277A1/en not_active Abandoned
- 2012-08-06 MX MX2014001475A patent/MX2014001475A/es not_active Application Discontinuation
- 2012-08-06 EP EP12756386.4A patent/EP2739723A1/en not_active Withdrawn
- 2012-08-06 RU RU2014108478/10A patent/RU2014108478A/ru not_active Application Discontinuation
- 2012-08-06 BR BR112014002718A patent/BR112014002718A8/pt not_active IP Right Cessation
- 2012-08-06 SG SG2014008080A patent/SG2014008080A/en unknown
- 2012-08-06 WO PCT/EP2012/065327 patent/WO2013020945A1/en not_active Ceased
- 2012-08-06 CN CN201280049453.2A patent/CN104011203A/zh active Pending
- 2012-08-06 KR KR1020147006060A patent/KR20140068936A/ko not_active Withdrawn
- 2012-08-06 AU AU2012293681A patent/AU2012293681A1/en not_active Abandoned
- 2012-08-06 CA CA2844106A patent/CA2844106A1/en not_active Abandoned
- 2012-08-06 JP JP2014523346A patent/JP2014527407A/ja active Pending
-
2014
- 2014-02-05 IL IL230830A patent/IL230830A0/en unknown
- 2014-03-05 CO CO14047158A patent/CO7081142A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL230830A0 (en) | 2014-03-31 |
| CO7081142A2 (es) | 2014-10-10 |
| EP2554662A1 (en) | 2013-02-06 |
| CA2844106A1 (en) | 2013-02-14 |
| BR112014002718A2 (pt) | 2017-06-13 |
| MX2014001475A (es) | 2014-07-22 |
| JP2014527407A (ja) | 2014-10-16 |
| AR087471A1 (es) | 2014-03-26 |
| EP2739723A1 (en) | 2014-06-11 |
| BR112014002718A8 (pt) | 2017-06-20 |
| WO2013020945A1 (en) | 2013-02-14 |
| KR20140068936A (ko) | 2014-06-09 |
| NZ621345A (en) | 2015-09-25 |
| AU2012293681A1 (en) | 2014-03-06 |
| US20140199277A1 (en) | 2014-07-17 |
| WO2013020945A9 (en) | 2013-04-04 |
| SG2014008080A (en) | 2014-03-28 |
| CN104011203A (zh) | 2014-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527407A5 (OSRAM) | ||
| ES2659980T3 (es) | Agente para promover la adherencia de células endoteliales de la córnea | |
| Wabik et al. | Switching roles: the functional plasticity of adult tissue stem cells | |
| US12157732B2 (en) | eIF4E inhibitors and uses thereof | |
| CA3097774A1 (en) | Pteridinone compounds and uses thereof | |
| JP2020517698A5 (OSRAM) | ||
| JP2016510727A5 (OSRAM) | ||
| US12234231B2 (en) | EIF4E inhibitors and uses thereof | |
| KR20140068936A (ko) | 망막 변성 질환의 치료방법 | |
| CN105518123B (zh) | 制备眼前段组织的方法 | |
| CN103539777B (zh) | Pi3激酶调节剂及其使用方法和用途 | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| EP1885454A2 (en) | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders | |
| CN106132934B (zh) | 治疗炎性病症的苯并咪唑衍生物及其医药组合物 | |
| JP2023116525A (ja) | 網膜細胞への線維芽細胞の再プログラミング方法 | |
| US20210330863A1 (en) | 5-hydroxytryptamine 1b receptor-stimulating agent for enhancing in vivo engraftment potential | |
| PE20150629A1 (es) | Derivados de etinilo como moduladores de la actividad del receptor de mglur5 | |
| JPWO2019044753A1 (ja) | 線維化抑制作用を有する細胞シート | |
| EP1879591B1 (en) | Use of azapaullones for preventing and treating pancreatic autoimmune disorders | |
| BR112012016128A8 (pt) | Agente terapêutico (y-39983) para disfunção endotelial da córnea | |
| ES2910654T3 (es) | Composiciones y métodos para mejorar la migración y el injerto de células madre hematopoyéticas | |
| Li et al. | Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy and Safety | |
| CA3154084A1 (en) | Feeder-based and feeder-free stem cell culture systems for stratified epithelial stem cells, and uses related thereto | |
| SG11202107707UA (en) | A fused ring heteroaryl compound as an alk4/5 inhibitor | |
| TW202430148A (zh) | ｅＩＦ４Ｅ抑制劑及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20170510 |